Cryotherapy & Oxaliplatin

Description

The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy.

Conditions

Colon Cancer, Peripheral Neuropathy

Study Overview

Study Details

Study overview

The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy.

A Phase II Randomized Interventional Pilot Study for Colon Cancer Patients Receiving Oxaliplatin: Benefits of Cryotherapy in Prevention of Peripheral Neuropathy

Cryotherapy & Oxaliplatin

Condition
Colon Cancer
Intervention / Treatment

-

Contacts and Locations

Mineola

NYU Langone Health, Mineola, New York, United States, 11501

New York

NYU Langone Health, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Over the age of 18 years
  • * Willingness to participate in research
  • * Diagnosed with stage III colon cancer
  • * Chemotherapy naïve
  • * Planning to initiate Capecitabine + Oxaliplatin (CAPOX) chemotherapy regimen as part of standard of care.
  • * Pre-existing peripheral neuropathy
  • * Pre-existing diabetes
  • * Raynaud's disease
  • * Metabolic syndrome, including: Hypertension; Hypercholesterolemia; and Obesity (BSA \> 2)
  • * Upper extremity amputees
  • * Specific autoimmune diseases: Guillain-Barre; Lupus; Rheumatoid arthritis; and Sjogren's syndrome

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NYU Langone Health,

Sarah Mendez, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2026-06-30